

### **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the Application. Additions are indicated by underlining, and deletions are indicated by strikethrough.

#### **Listing of Claims**

1. (Currently Amended) An amorphous form of olanzapine preparable by a process comprising the step of melting one or more crystalline forms of olanzapine.
2. (Original) An amorphous form of olanzapine as claimed in claim 1, wherein the olanzapine is in particulate form.
3. (Previously Presented) An amorphous form of olanzapine as claimed in claim 1, wherein the olanzapine is substantially pure.
4. (Previously Presented) An amorphous form of olanzapine as claimed in claim 1, having an IR spectrum substantially as shown in Figure One, an XRPD spectrum substantially as shown in Figure Two, and/or a DSC trace substantially as shown in Figure Three.
5. (Cancelled)
6. (Currently amended) A process for the preparation of an amorphous form of olanzapine ~~as claimed in claim 1,~~ comprising the step of melting one or more crystalline forms of olanzapine.
7. (Original) A process as claimed in claim 6, further comprising the step of cooling the melt.
- 8-11. (Cancelled)

12. (Previously Presented) A method of preparing a pharmaceutical composition, comprising utilizing an amorphous form of olanzapine as claimed in claim 1.
13. (Original) A method as claimed in claim 12, wherein the pharmaceutical composition is for oral or parenteral administration.
14. (Previously Presented) A method as claimed in claim 12, wherein the pharmaceutical composition is a tablet or capsule for oral administration.
15. (Previously Presented) A method as claimed in claim 12, wherein the pharmaceutical composition is a solution for oral or parenteral administration.
16. (Previously Presented) A pharmaceutical composition, comprising an amorphous form of olanzapine as claimed in claim 1.
17. (Original) A pharmaceutical composition as claimed in claim 16, further comprising a pharmaceutically acceptable carrier, excipient, or diluent.
18. (Currently Amended) A pharmaceutical composition as claimed in claim 16, wherein the composition is for oral or parenteral administration.
19. (Previously Presented) A pharmaceutical composition as claimed in claim 16, wherein the composition is in the form of a tablet or capsule for oral administration or in the form of a powder suitable for preparing a solution for oral or parenteral administration.
20. (Original) A pharmaceutical composition as claimed in claim 19, wherein the composition is in the form of a tablet or capsule and further comprises lactose, hydroxypropylcellulose, crospovidone, microcrystalline cellulose, magnesium stearate, gelatin and/or manitol.

21. (Original) A pharmaceutical composition as claimed in claim 19, wherein the composition is in the form of a powder and further comprises lactose, tartaric acid, hydrochloric acid and/or sodium hydroxide.
22. (Previously Presented) A pharmaceutical composition as claimed in claim 16, wherein the composition is in unit dosage form comprising from 1 mg to 30 mg amorphous olanzapine.
- 23-27. (Cancelled)
28. (Previously Presented) A method of treating a condition selected from a psychiatric, psychological, or psychotic disorder, an anxiety disorder, or a gastrointestinal or functional bowel disorder, comprising administering an effective amount of an amorphous form of olanzapine as claimed in claim 1, to a patient in need thereof.
29. (Original) A method as claimed in claim 28, wherein the patient is a human.
30. (Previously Presented) A method as claimed in claim 28, wherein the amount of an amorphous form of olanzapine administered is from 2 mg to 20 mg per day.
31. (Previously Presented) A method as claimed in claim 28, wherein the psychiatric, psychological or psychotic disorder is schizophrenia, schizophreniform disorder, schizoaffective disorder, Tourette's disorder, mania, manic episode, severe manic episode, delusional disorder, psychotic disorder, psychosis, bipolar disorder, depression, or a disorder of the central nervous system.
32. (Currently Amended) A method as claimed in claim 31, wherein the psychiatric, psychological, or psychotic disorder is schizophrenia, manic episode, severe manic episode, psychosis, or bipolar disorder.

33. (Previously Presented) A method as claimed in claim 28, wherein the anxiety disorder is generalized anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, or an anxiety state.
34. (Previously Presented) A method as claimed in claim 28, wherein the gastrointestinal or functional bowel disorder is irritable bowel syndrome, gastric hypermotility, ichlasia, hypertonic lower esophageal sphincter, tachygastria, constipation, diarrhoea, mucorrhoea, or pain or discomfort over the course of the sigmoid colon.
35. (New) A method of treating a condition selected from a psychiatric, psychological or psychotic disorder, an anxiety disorder, or a gastrointestinal or functional bowel disorder, comprising administering an effective amount of an amorphous form of olanzapine as claimed in claim 2, to a patient in need thereof.
36. (New) A method of treating a condition selected from a psychiatric, psychological or psychotic disorder, an anxiety disorder, or a gastrointestinal or functional bowel disorder, comprising administering an effective amount of an amorphous form of olanzapine as claimed in claim 3, to a patient in need thereof.
37. (New) A method of treating a condition selected from a psychiatric, psychological or psychotic disorder, an anxiety disorder, or a gastrointestinal or functional bowel disorder, comprising administering an effective amount of an amorphous form of olanzapine as claimed in claim 4, to a patient in need thereof.
38. (New) A method of treating a condition selected from a psychiatric, psychological or psychotic disorder, an anxiety disorder, or a gastrointestinal or functional bowel disorder, comprising administering an effective amount of a pharmaceutical composition as claimed in claim 16, to a patient in need thereof.

39. (New) A method of preparing a pharmaceutical composition comprising amorphous olanzapine, the method comprising the step of melting one or more crystalline forms of olanzapine.
40. (New) A pharmaceutical composition comprising amorphous olanzapine prepared by a process comprising the step of melting one or more crystalline forms of olanzapine.
41. (New) A pharmaceutical composition comprising amorphous olanzapine, wherein the composition is for sustained or delayed release.
42. (New) An amorphous form of olanzapine as claimed in claim 1 preparable by a process further comprising the step of cooling the melt.